Healthcare entity

Health Service Executive

Company

regulation is the sole category represented across all 1 tracked stories. European Union is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Health Service Executive appears in 1 tracked Healthcare story from August 16, 2026.

Last mentioned: Aug 16, 2026

Entity pulse

Recent coverage · Health Service Executive

1 story
6 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Health Service Executive

regulation is the sole category represented across all 1 tracked stories. European Union is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Health Service Executive appears in 1 tracked Healthcare story from August 16, 2026. The tracked stories average 2 original sources each.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 9 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Health Service Executive. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. HSE Drugs Group recommends against reimbursement

    The HSE Drugs Group cites limitations and uncertainties in evidence and price concerns in its non-recommendation for Skyclarys.

  2. Sinn Féin leader urges Taoiseach to intervene

    Mary Lou McDonald writes to Micheál Martin seeking full transparency and an urgent meeting with patients ahead of the final HSE decision.

  3. EU approves Skyclarys

    Skyclarys receives European Union marketing authorization for Friedreich's ataxia.

Stories mentioning Health Service Executive 1

Health Policy Neutral

Ireland PM Urged to Intervene as 200 Rare Disease Patients Await Drug

A political row has erupted in Ireland after the HSE Drugs Group advised against reimbursing Skyclarys for Friedreich's ataxia, leaving about 200 patients in limbo. Sinn Féin leader Mary Lou McDonald is demanding full transparency and Taoiseach intervention ahead of a final HSE decision later in August.

2 sources

Health Service Executive is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.